Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

NCT02128113 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02128113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02128113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
April 30, 2015
Enrollment
307 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cataract surgery, corneal endothelial cell loss, ocular inflammation, ocular pain